MS and co-morbid autoimmunity
In my experience, the most common co-morbid autoimmune disease in people with MS, outside of thyroid disease post-alemtuzumab, is MS-associated…
How to Care for 5 Joints Commonly Affected by Arthritis
RA can affect some joints more than others — usually the ones you rely on the most. Joints in the…
Stuart Schlossman
What to know about celiac disease
People with celiac disease experience inflammation and pain in the gut when they consume gluten. It is an autoimmune condition…
Stuart Schlossman
Biomarker found for potential new disorder that Has-Been labeled as MS (Learning more about #NMOSD, #MOG and #MOGAD)
Findings could pave way for more targeted treatments, researchers say by Marisa Wexler, MS | August 11, 2023 An antibody…
Stuart Schlossman
Clinical features of MOGAD with brainstem involvement in the initial attack versus NMOSD and MS – PubMed
This is a PubMed Article: https://pubmed.ncbi.nlm.nih.gov/37402345/ Qiao Xu 1, Xixi Yang 1, Zhandong Qiu 1, Dawei Li 1, Hongxing Wang 1, Hong Ye 1, Lidong Jiao 1, Jing Zhang 1, Li Di 1, Peng Lei 2, Huiqing Dong 1, Zheng Liu 3 Affiliations expand PMID: 37402345…
Stuart Schlossman
Study helps make clear distinctions between MS, MOGAD (Myelin oligodendrocyte glycoprotein antibody-associated disease)
February 25, 2023 The study was presented at the 2023 #ACTRIMS forum A new study set out to assess potentially…
Stuart Schlossman
Patient Perspectives on Generalized Myasthenia Gravis
READ MORE here Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews…
Stuart Schlossman
FDA approves drug for adults with generalized myasthenia gravis
April 28, 2022 AstraZeneca has announced FDA approval of #Ultomiris, a long-acting C5 complement inhibitor for the treatment of adults…
Stuart Schlossman
Multiple Sclerosis (MS) vs. Rheumatoid Arthritis (RA)
By Angelica Bottaro Published on April 27, 2022 Medically reviewed by Anita C. Chandrasekaran, MD, MPH Multiple…
Stuart Schlossman
Serum GFA Identified as a Biomarker for NMOSD, sNfL as a Predictor of Poor Post-Attack Outcomes
March 12, 2022 A systematic literature review of randomized controlled trials in neuromyelitis optica spectrum disorder was performed, with 7…
Stuart Schlossman
